ERBB2 and breast cancer: The limitations of this study relate primarily to the limitations of real-world data: as shown in Table 1, the use of SG and T-DXd is non-random across major breast cancer subsets, with SG-only patients being preferentially HER2-null and T-DXd-only patients being far more commonly HER2-low.